Clinical Trial Update: Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma [NA]

View source ↗

Summary

A pilot clinical trial evaluating topotecan, vincristine, and subconjunctival carboplatin for bilateral retinoblastoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinoblastoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Topotecan (topotecan)
• Vincristine (vincristine)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Retinoblastoma | NA | Status: WITHDRAWN